Karl Saardi, MD
Dermatology · Washington, DCNPI 1114312410
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 65.9% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2024 at $62,257 and has fallen 83.0% since, to $10,569 in 2025. Among dermatology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $267.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$66K
- UCB, Inc.$14K
- Galderma Laboratories, L.p.$8K
- Regeneron$4K
- AbbVie$2K
- Argenx US, Inc.$2K
- plus $5K from 28 others
Across 3 payments — averaging $629.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma AS$2K
What the payments were for
- Consulting fees$39,56739%
- Speaking & faculty fees$43,77543%
- Travel & lodging$8,9219%
- Food & beverage$8,3248%
- Education$3770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 53 | $66,489 |
| UCB, Inc. | 24 | $13,918 |
| Galderma Laboratories, L.p. | 4 | $8,028 |
| Regeneron | 9 | $4,224 |
| AbbVie | 95 | $1,767 |
| Argenx US, Inc. | 1 | $1,663 |
| Novartis | 29 | $653 |
| Johnson & Johnson | 13 | $649 |
| Amgen | 16 | $422 |
| Lilly USA, LLC | 17 | $384 |
| E.r. Squibb & Sons, L.L.C. | 7 | $364 |
| LEO Pharma Inc. | 21 | $340 |
| Pfizer | 18 | $321 |
| Incyte Corporation | 9 | $197 |
| Regeneron Healthcare Solutions, Inc. | 8 | $185 |
| Dermavant Sciences, Inc. | 6 | $181 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $181 |
| Arcutis Biotherapeutics, Inc. | 8 | $169 |
| Sanofi | 7 | $160 |
| Sun Pharmaceutical Industries Inc. | 5 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Kyowa Kirin, Inc. | 5 | $95 |
| Organon | 2 | $49 |
| Biofrontera Inc. | 2 | $44 |
| Almirall LLC | 2 | $39 |
| Springworks Therapeutics, Inc. | 2 | $35 |
| Merck | 1 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Biocon Biologics Inc | 1 | $30 |
| Journey Medical Corporation | 1 | $22 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| AstraZeneca | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,964 in reported general payments places this provider in the 90th percentile of 73 dermatology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Unoready PenSecukinumab | 42 | $491,774 |
| Humira(Cf) PenAdalimumab | 19 | $287,122 |
| Dupixent PenDupilumab | 72 | $259,794 |
| RemicadeInfliximab | 15 | $144,495 |
| Humira PenAdalimumab | 15 | $116,240 |
| Taltz AutoinjectorIxekizumab | 14 | $97,616 |
| RinvoqUpadacitinib | 12 | $77,297 |
| ZoryveRoflumilast | 26 | $22,282 |
| Tacrolimus | 37 | $4,015 |
| Clobetasol Propionate | 60 | $3,811 |
| Pimecrolimus | 13 | $3,134 |
| Metronidazole | 13 | $1,036 |
| Clindamycin Phosphate | 33 | $1,002 |
| Triamcinolone Acetonide | 82 | $866 |
| Fluocinonide | 15 | $823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRemicade | $649 | $144,49515 claims |
| AbbVieRinvoq | $1,767 | $77,29712 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $169 | $22,28226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 dermatology providers in District of Columbia.
Other dermatology in Washington
- Jonathan SilverbergWashington$4.5M
- Adam FriedmanWashington$2.2M
- Terrence KeaneyWashington$1.1M
- Candrice HeathWashington$168K
- Agnes ChangWashington$109K
- Todd PerkinsWashington$102K
- Noelle SherberWashington$96K
- Yolanda HolmesWashington$80K
- Cheri FreyWashington$79K
- Ginette OkoyeWashington$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.